## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Ty	pe Response	s)															-	
1. Name and Address of Reporting Person* Butchko Julia G.					2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]							:	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) C/O IMMUNOVANT, INC., 320 W 37TH STREET, 6TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 08/03/2021								X Officer (give title below) Other (specify below)  Chief Dev. & Tech. Officer					
(Street) NEW YORK, NY 10018					4. If Amendment, Date Original Filed(Month/Day/Year)							-	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City		(State)	(	(Zip)		T	able I - Noi	n-Dei	rivative S	Securi	ities A	cqui	red, Dispo	osed of, or E	Beneficially	Owned		
1.Title of Security (Instr. 3)		1	Date	nsaction h/Day/Year)		ution Date, if	(Instr. 8)	ction	4. Securities Ad (A) or Disposed (Instr. 3, 4 and		sed of	l of (D) Bene 5) Repo		Amount of Securities deneficially Owned Following deported Transaction(s)		6. Ownership Form:	7. Nature of Indirect Beneficial	
					(Mor	nth/Day/Year)	Code	V	Amour	(	A) or D) P	rice	(Instr. 3 a	nd 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common	Stock (1)	(	08/03/	2021			A		285,30	06 A	. \$	0 8	344,806			D		
						outs, calls, w	arrants, op						y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3.7 Ex	A. Deemed xecution Da	(e.g., ]	4. Transaction Code	ies Acquire arrants, op	ed, Disposed of, ontions, convertible  6. Date Exercisab and Expiration Date (Month/Day/Year		of, or tible s cisable on Dat	r Beneficies securities ole 7. date Ar.				of 9. Number of Derivative Securities	of 10. Ownersl Form of	Ownershi (Instr. 4)	
							Disposed of (D) (Instr. 3, 4, and 5)											
						Code V	(A) (D)	Date Exe	-	Expira Date	ation	Title	Amount or Number of Shares					
Repor	ting O	wners																
					Relationships													
Reporting Owner Name / Address			ss	Director	10% Officer				Othe			r						

Chief Dev. & Tech. Officer

### **Signatures**

Butchko Julia G.

C/O IMMUNOVANT, INC.

NEW YORK, NY 10018

320 W 37TH STREET, 6TH FLOOR

/s/ Pamela Yanchik Connealy, attorney-in-fact for Julia G. Butchko	08/04/2021
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents the number of shares underlying restricted stock units awards ("RSUs").
- (2) 50% of the RSUs will vest on January 1, 2022 and the remainder of the RSUs will vest on January 1, 2023, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.